Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/17817
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRamasamy, Barathy Rani-
dc.contributor.authorCharles, Patrick G P-
dc.contributor.authorJohnson, Douglas F-
dc.contributor.authorFrauman, Albert-
dc.date2017-09-01-
dc.date.accessioned2018-05-28T06:14:03Z-
dc.date.available2018-05-28T06:14:03Z-
dc.date.issued2017-09-01-
dc.identifier.citationBMJ Case Reports 2017; 2017: bcr-2017-220184-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/17817-
dc.description.abstractA 32-year-old man who was receiving adalimumab for seronegative rheumatoid arthritis presented with a 4-week history of fever, night sweats, fatigue, myalgias and diarrhoea. On examination, he had obvious splenomegaly but no lymphadenopathy or pharyngitis. Full blood count revealed mild neutropenia and significant lymphocytosis, with a blood film showing atypical lymphocytes. Liver function tests were mildly deranged with a mixed hepatitic and obstructive pattern. Ultrasound confirmed massive splenomegaly with a span of 21 cm in the long axis. Serological tests confirmed the presence of both primary Epstein-Barr virus and cytomegalovirus infections. The patient had his adalimumab withheld, was treated with supportive measures and improved over a period of 8 weeks. He remained well 5 months after the onset of illness with complete normalisation of blood count and a resolution of the splenomegaly.-
dc.language.isoeng-
dc.subjectInfectious diseases-
dc.subjectrheumatoid arthritis-
dc.subjectunwanted effects / adverse reactions-
dc.titleMassive splenomegaly due to concurrent primary Epstein-Barr virus and cytomegalovirus infection in a patient on adalimumab.-
dc.typeJournal Article-
dc.identifier.journaltitleBMJ Case Reports-
dc.identifier.affiliationDepartment of General Medicine, Austin Health, Heidelberg, Victoria, Australia-
dc.identifier.affiliationDepartment of Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia-
dc.identifier.affiliationDepartment of Clinical Pharmacology and Therapeutics, Austin Health, Heidelberg, Victoria, Australia-
dc.identifier.doi10.1136/bcr-2017-220184-
dc.identifier.pubmedid28864556-
dc.type.austinCase Reports-
dc.type.austinJournal Article-
local.name.researcherCharles, Patrick G P
item.grantfulltextnone-
item.openairetypeJournal Article-
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
crisitem.author.deptGeneral Medicine-
crisitem.author.deptInfectious Diseases-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

40
checked on Nov 23, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.